Breaking News Instant updates and real-time market news.

IDRA

Idera Pharmaceuticals

$1.39

(0.00%)

, BCRX

BioCryst

$6.12

-0.03 (-0.49%)

16:05
07/10/18
07/10
16:05
07/10/18
16:05

Idera announces termination of merger agreement with BioCryst

Idera Pharmaceuticals (IDRA) announced that the merger agreement entered into by and among Idera and BioCryst (BCRX) on January 22 has been terminated. The agreement was terminated following the July 10 special meeting of BioCryst stockholders at which BioCryst's stockholders voted against the proposed mergers. Separately, a majority of Idera's stockholders voted in favor of the adoption of the agreement at a special meeting of Idera stockholders, also held on July 10. As part of the merger agreement, BioCryst will reimburse Idera $6M in connection with the termination. "The Board and shareholders of Idera overwhelmingly supported the proposed merger with BioCryst based on the strategic rationale, operating synergies and opportunity to create a stronger and more diversified rare-disease, focused organization," stated Vincent Milano, Idera's Chief Executive Officer. "Our tilsotolimod would have been one of the two centerpiece product opportunities of the combined company. As we move forward independently, we will remain focused on the development of tilsotolimod in anti-PD-1 refractory melanoma, a significant unmet need, as well as begin to explore the role of tilsotolimod in improving outcomes in patients suffering from additional solid tumor cancers. While we remain focused on the development of tilsotolimod, if an opportunity arises to further enhance shareholder value and build our company through business development, we will explore it."

IDRA

Idera Pharmaceuticals

$1.39

(0.00%)

BCRX

BioCryst

$6.12

-0.03 (-0.49%)

  • 10

    Jul

  • 10

    Jul

IDRA Idera Pharmaceuticals
$1.39

(0.00%)

11/09/17
HCWC
11/09/17
INITIATION
Target $4
HCWC
Buy
Idera Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Idera Pharmaceuticals with a Buy rating and $4 price target. The company's two lead products have "significant potential in the fast growing immunotherapy market," the analyst contends.
11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
PIPR
11/09/17
NO CHANGE
Target $4
PIPR
Overweight
Piper reiterates Overweight rating on Idera after IMO-2125 trial update
After Idera Pharmaceuticals reported a 5th unconfirmed RECIST response in its ongoing IMO-2125 plus Yervoy combo trial in PD-1 refractory metastatic melanoma, bringing the ORR to 50%, Piper Jaffray analyst Edward Tenthoff reiterated his Overweight rating and $4 price target on the stock, which is up 15% to $2.03 in midday trading.
06/13/18
JMPS
06/13/18
NO CHANGE
Target $4
JMPS
Outperform
Idera Pharmaceuticals price target lowered to $4 from $8 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis lowered his price target on Idera Pharmaceuticals to $4 from $8 after the company's Phase 2 trial of IMO-8400 in the dermatomyositis setting did not meet its primary endpoint. While he views this latest development for IMO-8400 as disappointing, he reminds investors of the positive tilsotolimod data recently presented at ASCO and still thinks tilsotolimod plus ipilimumab has the potential for a favorable competitive profile in the anti PD-1 refractory melanoma setting. Aprilakis keeps an Outperform rating on Idera shares.
BCRX BioCryst
$6.12

-0.03 (-0.49%)

01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
BioCryst upgraded to Outperform from Sector Perform at RBC Capital
01/02/18
RBCM
01/02/18
UPGRADE
Target $8
RBCM
Outperform
BioCryst upgraded to Outperform at RBC Capital on BCX7353 performance
As reported earlier, RBC Capital analyst Brian Abrahams upgraded BioCryst to Outperform from Sector Perform and raised his price target to $8 from $6. Abrahams says the lead drug BCX7353 showed a clear reduction in hereditary angioedema attacks in its phase 2 study, while its lack of dose dependence is "legitimately explainable by misidentification of GI side effects at the higher doses". The analyst adds that the recent FDA precedent also implies a "relatively low bar for approvals of drugs to treat rare, potentially fatal diseases".
06/22/18
GHSC
06/22/18
INITIATION
GHSC
Neutral
BioCryst initiated with a Neutral at Seaport Global
Seaport Global initiated BioCryst (BCRX) with a Neutral due to uncertainty on its proposed merger with Idera Pharmaceuticals (IDRA) and views risk/reward as balanced.
06/22/18
06/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunlands Online (STG) initiated with an Outperform at Credit Suisse. 2. Micron (MU) initiated with a Buy at Benchmark. 3. Interpace Diagnostics (IDXG) initiated with a Buy at Ladenburg. 4. Alteryx (AYX) initiated with an Outperform at Oppenheimer. 5. BioCryst (BCRX) initiated with a Neutral at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:38
07/17/18
07/17
07:38
07/17/18
07:38
Hot Stocks
Goldman Sachs reports Q2 FICC revenue $1.68B, 45% higher than last year »

Net revenues in Fixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$36.92

3 (8.84%)

07:38
07/17/18
07/17
07:38
07/17/18
07:38
Technical Analysis
Technical Take: iQIYI falls, completes Skymoons acquisition »

The shares of iQIYI (IQ)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCR

Novocure

$35.60

2.5 (7.55%)

07:37
07/17/18
07/17
07:37
07/17/18
07:37
Hot Stocks
Novocure announces scientific track for tumor treating fields at EMBS »

Novocure announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

RVI

Retail Value

$35.60

-0.36 (-1.00%)

, DDR

DDR Corp.

$14.31

-0.045 (-0.31%)

07:36
07/17/18
07/17
07:36
07/17/18
07:36
Initiation
Retail Value, DDR Corp. initiated  »

Retail Value initiated…

RVI

Retail Value

$35.60

-0.36 (-1.00%)

DDR

DDR Corp.

$14.31

-0.045 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:36
07/17/18
07/17
07:36
07/17/18
07:36
Hot Stocks
Goldman Sachs reports Q2 annualized ROE 12.8% »

Annualized return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$2.64

-0.12 (-4.35%)

07:35
07/17/18
07/17
07:35
07/17/18
07:35
Hot Stocks
22nd Century comments on FDA's ANPRM to lessen nicotine in cigarettes »

22nd Century responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

, MSFT

Microsoft

$104.91

-0.51 (-0.48%)

07:35
07/17/18
07/17
07:35
07/17/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

NFLX

Netflix

$400.24

4.32 (1.09%)

MSFT

Microsoft

$104.91

-0.51 (-0.48%)

SNAP

Snap

$13.07

-0.295 (-2.21%)

FOXA

21st Century Fox

$46.71

-0.84 (-1.77%)

MS

Morgan Stanley

$48.91

0.85 (1.77%)

TGT

Target

$77.20

-0.525 (-0.68%)

FSLR

First Solar

$53.99

-0.08 (-0.15%)

CZR

Caesars

$11.63

0.075 (0.65%)

FTI

TechnipFMC

$30.58

-0.36 (-1.16%)

HFC

HollyFrontier

$68.91

0.25 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 02

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

BCRX

BioCryst

$6.20

0.01 (0.16%)

07:34
07/17/18
07/17
07:34
07/17/18
07:34
Upgrade
BioCryst rating change  »

BioCryst upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:33
07/17/18
07/17
07:33
07/17/18
07:33
Earnings
Goldman Sachs reports Q2 EPS $5.98, consensus $4.66 »

Reports Q2 revenue $9.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

, LB

L Brands

$32.01

0.31 (0.98%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Columbus signs renewal agreement with Victoria's Secret »

Alliance Data Systems…

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

LB

L Brands

$32.01

0.31 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

PRIM

Primoris

$28.12

-0.51 (-1.78%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Primoris announces electrical distribution award valued over $75M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$41.10

1.38 (3.47%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Recommendations
Zscaler analyst commentary  »

Zscaler price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

, QEP

QEP Resources

$12.09

-0.67 (-5.25%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

QEP

QEP Resources

$12.09

-0.67 (-5.25%)

HUBG

Hub Group

$49.10

-1.85 (-3.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 19

    Aug

RPM

RPM

$60.00

-0.54 (-0.89%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Downgrade
RPM rating change  »

RPM downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

OSUR

OraSure

$16.28

-1.04 (-6.00%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Recommendations
OraSure analyst commentary  »

OraSure weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

07:26
07/17/18
07/17
07:26
07/17/18
07:26
Recommendations
Netflix analyst commentary  »

Canaccord views Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

ElectroCore

$14.49

-0.51 (-3.40%)

07:25
07/17/18
07/17
07:25
07/17/18
07:25
Initiation
ElectroCore initiated  »

ElectroCore initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$30.58

-0.36 (-1.16%)

07:24
07/17/18
07/17
07:24
07/17/18
07:24
Initiation
TechnipFMC initiated  »

TechnipFMC assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

QTS

QTS Realty Trust

$40.90

-0.05 (-0.12%)

07:23
07/17/18
07/17
07:23
07/17/18
07:23
Initiation
QTS Realty Trust initiated  »

QTS Realty Trust resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BA

Boeing

$356.01

5.2 (1.48%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Hot Stocks
Boeing signs integrated services agreement with Blackshape »

Boeing announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Oppenheimer remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INXN

Interxion

$64.05

0.77 (1.22%)

07:21
07/17/18
07/17
07:21
07/17/18
07:21
Initiation
Interxion initiated  »

Interxion resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

07:20
07/17/18
07/17
07:20
07/17/18
07:20
General news
FX Update: The Dollar remained on a softening tack »

FX Update: The Dollar…

BAESY

BAE Systems

$0.00

(0.00%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Periodicals
BAE Systems wants international partners for UK fighter project, Reuters says »

BAE Systems wants to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.